Comparative Pharmacology
Head-to-head clinical analysis: TREPROSTINIL versus VENTAVIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TREPROSTINIL versus VENTAVIS.
TREPROSTINIL vs VENTAVIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Treprostinil is a synthetic prostacyclin analogue that directly vasodilates pulmonary and systemic arterial beds, inhibits platelet aggregation, and suppresses vascular smooth muscle proliferation via activation of IP receptors and subsequent increase in cAMP levels.
Ventavis (iloprost) is a synthetic prostacyclin analog that causes vasodilation by increasing cyclic adenosine monophosphate (cAMP) levels in vascular smooth muscle cells, leading to relaxation and inhibition of platelet aggregation.
Continuous subcutaneous or intravenous infusion via infusion pump. Initial rate: 1.25 ng/kg/min; if not tolerated, reduce to 0.625 ng/kg/min. Titrate in increments of 1.25 ng/kg/min per week for first 4 weeks, then 2.5 ng/kg/min per week as tolerated. Typical maintenance dose: 25-40 ng/kg/min. Duration: continuous long-term.
Inhaled: 2.5 mcg or 5 mcg via I-neb AAD system, 6 to 9 times daily (maximum 45 mcg/day). Titrate based on response and tolerability.
None Documented
None Documented
Clinical Note
moderateTreprostinil + Benzydamine
"The risk or severity of adverse effects can be increased when Treprostinil is combined with Benzydamine."
Clinical Note
moderateTreprostinil + Droxicam
"The risk or severity of adverse effects can be increased when Treprostinil is combined with Droxicam."
Clinical Note
moderateTreprostinil + Loxoprofen
"The risk or severity of adverse effects can be increased when Treprostinil is combined with Loxoprofen."
Clinical Note
moderateTreprostinil + Clonixin
Terminal half-life is approximately 4 hours for intravenous administration; clinical context: requires continuous infusion due to short half-life.
Terminal elimination half-life: 0.45–1.0 hour (intravenous). Short half-life necessitates continuous intravenous or frequent nebulized administration for sustained effect.
Primarily hepatic metabolism via CYP2C8; renal excretion of unchanged drug is approximately 4% of the dose.
Renal: ~6% as unchanged drug; biliary/fecal: minimal; extensive hepatic metabolism with metabolites primarily excreted in urine (50-60% of total clearance). No significant renal or biliary excretion of parent drug.
Category A/B
Category C
Prostacyclin Analog
Prostacyclin Analog
"The risk or severity of adverse effects can be increased when Treprostinil is combined with Clonixin."